<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105348</url>
  </required_header>
  <id_info>
    <org_study_id>DM and IBD</org_study_id>
    <nct_id>NCT04105348</nct_id>
  </id_info>
  <brief_title>Diabetes Mellitus and Inflammatory Bowel Disease</brief_title>
  <official_title>The Association of Diabetes Mellitus and Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus is a hyperglycemic metabolic disorder due to insulin deficiency or
      resistance at its receptors, leads to impaired glucose metabolism and multi-organ affection;
      (optic, peripheral neurological, cardiovascular and renal).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory bowel disease; (Crohn's disease and ulcerative colitis), is chronic relapsing
      inflammation in the gastrointestinal tract due to complex interactions among genetic,
      environmental, gut microbiome, and immunologic factors.

      Inflammatory bowel disease treatment inhibits the abnormal inflammatory response to heal
      intestinal tissue, relieve the abdominal pain, the diarrhea and the fresh bleeding per
      rectum, also decreases the frequency of flare-ups and maintains remission.

      Amino-salicylates and antibiotics are step I drugs act on the intestinal lining and on
      presented inflammatory masses.

      Corticosteroids are step II drugs on failure of step I drugs for adequate control of the
      Inflammatory bowel disease and rapid relief of symptoms and inflammation.

      The immune modifying agents as azathioprine and 6 mercaptopurine are step III drugs on
      failure of the steroids.

      Biologic agents are anti Tumor necrotic factor agents (infliximab and adalimumab) and non
      anti Tumor necrotic factor agents (vedolizumab, ustekinumab and natalizumab).

      Inflammatory bowel disease may have endocrinal and metabolic associations in the form of;
      lipid abnormalities and insulin resistance. Also, insulin resistance and hyperglycemia may be
      due to steroid use as steroid upgrades (hepatic gluconeogenesis, inhibition of glucose uptake
      in adipose tissue, and impairment of insulin action).

      There is no epidemiological evidence that Inflammatory bowel disease is a definite risk
      factor for diabetes. In this study, the association of diabetes in patients with Inflammatory
      bowel disease will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>effect of IBD on DM</measure>
    <time_frame>on addmision</time_frame>
    <description>patients with raised; HbA1c, fasting blood glucose, 2 hours postprandial blood glucose</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>IBD with DM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>IBD without DM</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HbA1c</intervention_name>
    <description>patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2</description>
    <arm_group_label>IBD with DM</arm_group_label>
    <arm_group_label>IBD without DM</arm_group_label>
    <other_name>fasting blood glucose</other_name>
    <other_name>2 hours postprandial blood glucose</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        IBD clinic or Patients addmited at El raghy hospital in assiut university with IBD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - All patients with IBD admitted at EL-Raghy Assiut university hospital in the period of
        first of October 2019 to the end of September 2020 The diagnosis of DM is confirmed by high
        random blood glucose level more than 200mg/dl three times per day or high HbA1c more than
        6.5%.

        The diagnosis of IBD is confirmed by colonic biopsy results after colonoscopy.

        Exclusion Criteria:

          -  Patients didn't do colonoscopy or didn't get biopsy or with normal colonoscopy and
             biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fatema Abd El-Moez, professor</last_name>
    <phone>00201006564000</phone>
    <email>fatemaelosily@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lobna Ahmed, assisstant professor</last_name>
    <phone>00201093337630</phone>
    <email>lobna_wahid@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26.</citation>
    <PMID>29496507</PMID>
  </reference>
  <reference>
    <citation>Basso PJ, Fonseca MT, Bonf√° G, Alves VB, Sales-Campos H, Nardini V, Cardoso CR. Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease. Braz J Med Biol Res. 2014 Sep;47(9):727-37. Epub 2014 Jul 25. Review.</citation>
    <PMID>25075576</PMID>
  </reference>
  <reference>
    <citation>Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr;96(4):1116-22.</citation>
    <PMID>11316157</PMID>
  </reference>
  <reference>
    <citation>Tigas S, Tsatsoulis A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol. 2012;25(1):37-44. Review.</citation>
    <PMID>24714153</PMID>
  </reference>
  <reference>
    <citation>van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009 Feb;39(2):81-93. doi: 10.1111/j.1365-2362.2008.02067.x. Review.</citation>
    <PMID>19200161</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>September 29, 2019</last_update_submitted>
  <last_update_submitted_qc>September 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>MM Youssif</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

